^
Association details:
| Biomarker: | KDR elevation |
|---|---|
| Cancer: | Skin Cancer |
| Drug: | Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).
Published date:
05/16/2018
Excerpt:
...phase II study of pazopanib in patients…received pazo 800 mg qd. High plasma level of soluble VEGFR2 was associated with tumor response (p = 0.01)….suggest that pazo is a therapeutic option in DFSP....dermatofibrosarcoma protuberans (DFSP)...
DOI:
10.1200/JCO.2018.36.15_suppl.11557
Trial ID:
